Document is current
Any future updates will be listed below
-
Authors
Lakatos, Kornél
González, Germán
Hoballah, Jawad
Brooker, Jeff
Jeong, Sinyoung
Evans, Conor
Krauledat, Petra
Hansen, W. Peter
Elias, Kevin M.
Patankar, Manish
Fülöp, Vilmos
Konstantinopoulos, Panagiotis A.
Cramer, Daniel W.
-
Funding
Funding for this research was provided by:
national institutes of health (5R35CA197605)
- License Information
-
More Information
Article History
Received: 22 July 2021
Accepted: 3 February 2022
First Online: 26 February 2022
Declarations
:
: In 2016, we began collecting blood to study MUC16-binding to PBMCs in women with presumed ovarian cancer prior to any therapy at the Dana Farber Cancer Institute (DFCI IRB protocol 16–255) and later from healthy women through the Brigham and Women’s Hospital (BWH IRB protocol 2018P001677). A patient who had been diagnosed with stage IIIC high-grade serous ovarian learned about the protocol and requested her blood be studied. She was informed that results could not be used in her clinical care, provided consent, and granted a single-subject IRB exemption. IRB approval from Brigham and Women’s Hospital Institutional Review Board and patient consent were obtained for this study; a copy of the consent form is on file.
: All authors agreed to the publication of this data.
: G.G., W.P.H. and P.K. are employees of PNP Research Corp. J.B. and J.H. are, or were, employees of Thorlabs Imaging Sciences.
